Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

11.60 +0.31 (+2.70%)
Streaming Delayed Price Updated: 12:55 PM EDT, Sep 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?
Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, CleanSpark, Enovix Corp, Axcelis Tech, Intellia Therapeutics, Korn Ferry. 
Via Benzinga
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a... 
Via Benzinga
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
These companies could generate explosive growth over time. 
Via The Motley Fool
These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now
Neither word has anything to do with money -- at least not yet. 
Via The Motley Fool
Cracking The Code: Understanding Analyst Reviews For Intellia Therapeutics
 
Via Benzinga
Why Intellia Therapeutics, Inc. Outpaced the Stock Market
Investors will be eagerly watching for the performance of Intellia Therapeutics, Inc. in its upcoming earnings disclosure. 
Via Talk Markets
2 Stocks Down 30% to Buy Right Now
These stocks have plenty of catalysts ahead. 
Via The Motley Fool
Cathie Wood-Led Ark Invest Buys $9.9M Worth Of Amazon Shares, Also Picks Up Reddit Stock
 
Via Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The widely followed growth investor made big moves as May came to a close. 
Via The Motley Fool
The 3 Best Biotech Stocks to Buy in June 2024
Explore the best biotech stocks to buy in June 2024, with insights on Protagonist, BridgeBio and Intellia. 
Via InvestorPlace
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?
In keeping with Cathie Wood's style, these picks are riskier than average. 
Via The Motley Fool
Why Intellia Therapeutics Shares Are Trading Higher Monday
Intellia's NTLA-2002 is an experimental CRISPR based gene-editing therapy being developed as a one-time treatment for hereditary angioedema (HAE). The company announced the single does treatment led to... 
Via Benzinga
Is Intellia Therapeutics Stock a Buy Now?
The company's future will depend on its innovative qualities. 
Via The Motley Fool
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Cathie Wood-Led Ark Invest Sells Nearly $28M Worth Of Robinhood Shares Amid Crypto API Launch And Lackluster Bitcoin Price Action
On Thursday, Cathie Wood-led Ark Invest made notable adjustments to its portfolio, including a significant sell-off of Robinhood Markets Inc (NASDAQ:HOOD) shares. 
Via Benzinga
Cathie Wood's Ark Innovation ETF Sees Sharp Decline Among Top Holdings — Here Are 10-Largest Losers Within ARKF
Cathie Wood's flagship ARK Innovation ETF has been navigating through significant losses, showcasing the challenges faced by some of its major holdings. 
Via Benzinga
Topics ETFs
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor keeps adding to some of her favorite falling stocks. 
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor bought into one of Thursday's biggest losers and two stocks that have fallen sharply over the past year. 
Via The Motley Fool
NTLA Stock Earnings: Intellia Therapeutics Beats EPS, Beats Revenue for Q1 2024
NTLA stock results show that Intellia Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Just Say No to Drugs: 3 Pharma Stocks to Avoid
Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios. 
Via InvestorPlace
Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street’s Radar
The gene editing stocks are worth tuning into as some investors out there discount their innovative, albeit early-stage pipelines. 
Via InvestorPlace
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion. 
Via InvestorPlace
Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.
These two stocks could be ripe for a rebound. 
Via The Motley Fool
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
These stocks, a bargain today, are players to hold on to for the long term. 
Via The Motley Fool
Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm
--News Direct-- 
Via News Direct
ARKK’s Tech Bets: Over 500k Roblox Shares Purchased, 1.24M Robinhood Shares Sold
Cathie Wood's ARK Innovation ETF had an active trading week, with notable transactions including the purchase of over 500k Roblox shares and the sale of 1.247 million shares of Robinhood Markets. 
Via Talk Markets
Topics ETFs
Better Cathie Wood Stock: Moderna vs. Intellia
Moderna and Intellia have declined in the double digits over the past year. 
Via The Motley Fool
Hot Stocks: The 3 Best Opportunities for Investing in Biotech
Biotech stocks can offer some of the best risk vs. reward payoff in the stock market. These three are ones to buy now. 
Via InvestorPlace
3 Stocks That Could Be the Next Big Thing in Gene Editing
Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks. 
Via InvestorPlace
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst
2024 could see the start of its first late-stage clinical trials. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.